Openbookopenbook
Equity
4BASEBIO UK SOCIETAS(4BB)
GBX --+0.00%
Reward55Moderate
Risk54Moderate
📊75%Data
Revenue growing 258% YoY
4BB
+0.0 · +0.00%
GBX · LSE
4BASEBIO UK SOCIETAS | Healthcare
Profitless Growth
Market Cap:81.37M
ℹ️
Reward Rating
55
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 4BB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 1700p.

What is 4BASEBIO UK SOCIETAS?

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally.

4BB · Verdict

Solid reward · elevated risk

4BB stands out on balance sheet and growth, but watch the cash flow signal.

Based on 88% data coverage

4BB · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet76/100

    Current ratio 11.30

  • Growth73/100

    Rev +40.3% CAGR · earnings +56.2%

Watchouts 2

  • Cash flow16/100

    -1320% free-cash-flow margin

  • Profitability32/100

    -1322% net margin · -209% ROE

Model-based scoring. For information only — not financial advice.

What is 4BASEBIO UK SOCIETAS?

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccines and therapeutics; and oeDNA, or open ended DNA, a linear, double stranded DNA product ideal for genome editing. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 81.37M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap81.37M
P/E RatioN/A
Dividend YieldN/A
52 Week High1150
52 Week Low468
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding15M
No. of Employees110
IndustryBiotechnology
ExchangeLSE
Beta0.882
CurrencyGBX · Reports in GBP
Websitewww.4basebio.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.